Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Gotlib

Showing results (121-130 of 210) with videos related to

Pageof 21
Sort By:
Leukemia Research|July 25, 2025
Avapritinib versus midostaurin or cladribine in advanced systemic mastocytosis: A retrospective real-world external control studyAndreas Reiter, Jason Gotlib, Iván Álvarez-Twose, et al.
Expert Review of Hematology|April 6, 2012
Pathogenesis and classification of eosinophil disorders: a review of recent developments in the fieldPeter Valent, Gerald J Gleich, Andreas Reiter, et al.
Blood Advances|September 10, 2021
Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistanceJustin Anthony Chen, Yanli Hou, Krishna M Roskin, et al.
Leukemia|March 13, 2024
Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines CommitteeDonal P McLornan, Tomasz Czerw, Gandhi Damaj, et al.
Nature Medicine|December 7, 2021
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trialDaniel J DeAngelo, Deepti H Radia, Tracy I George, et al.
Blood|June 24, 2005
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutationJason Gotlib, Caroline Berubé, Joseph D Growney, et al.
Leukemia|July 5, 2022
Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosisAndreas Reiter, Jason Gotlib, Iván Álvarez-Twose, et al.
NEJM Evidence|August 26, 2025
Pemigatinib for Myeloid/Lymphoid Neoplasms with <i>FGFR1</i> RearrangementSrdan Verstovsek, Jean-Jacques Kiladjian, Alessandro M Vannucchi, et al.
Ebiomedicine|December 6, 2017
Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus ProposalPeter Valent, Cem Akin, Michel Arock, et al.
The New England Journal of Medicine|May 10, 2013
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CMLJulia E Maxson, Jason Gotlib, Daniel A Pollyea, et al.
Pageof 21

Showing results (121-130 of 210) with videos related to

Sort By:
Pageof 21
Leukemia Research|July 25, 2025
Avapritinib versus midostaurin or cladribine in advanced systemic mastocytosis: A retrospective real-world external control studyAndreas Reiter, Jason Gotlib, Iván Álvarez-Twose, et al.
Expert Review of Hematology|April 6, 2012
Pathogenesis and classification of eosinophil disorders: a review of recent developments in the fieldPeter Valent, Gerald J Gleich, Andreas Reiter, et al.
Blood Advances|September 10, 2021
Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistanceJustin Anthony Chen, Yanli Hou, Krishna M Roskin, et al.
Leukemia|March 13, 2024
Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines CommitteeDonal P McLornan, Tomasz Czerw, Gandhi Damaj, et al.
Nature Medicine|December 7, 2021
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trialDaniel J DeAngelo, Deepti H Radia, Tracy I George, et al.
Blood|June 24, 2005
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutationJason Gotlib, Caroline Berubé, Joseph D Growney, et al.
Leukemia|July 5, 2022
Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosisAndreas Reiter, Jason Gotlib, Iván Álvarez-Twose, et al.
NEJM Evidence|August 26, 2025
Pemigatinib for Myeloid/Lymphoid Neoplasms with <i>FGFR1</i> RearrangementSrdan Verstovsek, Jean-Jacques Kiladjian, Alessandro M Vannucchi, et al.
Ebiomedicine|December 6, 2017
Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus ProposalPeter Valent, Cem Akin, Michel Arock, et al.
The New England Journal of Medicine|May 10, 2013
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CMLJulia E Maxson, Jason Gotlib, Daniel A Pollyea, et al.
Pageof 21